In a significant medical advancement, Ractigen Therapeutics has initiated its first-ever human clinical trial for RAG-01, a novel small activating RNA (saRNA) treatment for NMIBC.

Verismo Therapeutics, a company specializing in CAR T-cell therapies, is progressing with its second clinical trial using the SynKIR™ platform.

Moderna, a biotechnology company, has reported preliminary results from a phase 1/2 clinical trial for mRNA-3927.

Achilles Therapeutics plc has reported interim Phase I/IIa clinical trial data for clonal neoantigen reactive T cells (cNeT) from the CHIRON study for non-small cell lung cancer (NSCLC) and the THETIS study for malignant melanoma

This innovative vaccine, developed by CureVac, is multivalent and contains antigens that match the four flu strains recommended by the World Health Organization (WHO).

Eilean Therapeutics LLC has received approval from the Human Research Ethics Committee in Australia to commence a Phase I clinical trial for lomonitinib (ZE46-0134).

A recent Phase 1b clinical trial of topical pravibismane for managing moderate to severe diabetic foot ulcers has shown promising results.

TPST-1120, a novel oral PPAR⍺ inhibitor, has shown promising results in treating cancers that are resistant to PD-1 inhibitors and those with weakened immune systems.

LOTIS-7 Phase 1b Trial Completes Dose Escalation: ZYNLONTA® and Bispecific Antibodies for Non-Hodgkin Lymphoma Patients, No Severe Side Effects Observed.

Ocugen, Inc. has received approval from the Data and Safety Monitoring Board (DSMB) to advance to the medium dose cohort in the Phase 1/2 clinical trial for OCU410.

Geneos Therapeutics has reported successful results from its GT-30 clinical trial, showcasing the safety and effectiveness of a personalized therapeutic cancer vaccine (PTCV) for patients with advanced hepatocellular carcinoma (HCC).

The study, which focuses on the use of RP1 monotherapy for skin cancer treatment in transplant patients, was detailed at the AACR 2024 Annual Meeting.